All the news Showing 3 of 23 articles from: EASL 2018Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NAFLD Cenicriviroc treatment improves liver fibrosis in people with NASH Liz Highleyman / 13 April 2018 Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, continued to show an anti-fibrotic effect in people with non-alcoholic steatohepatitis (NASH) after two years of follow-up, according to a ... Treatment for people who use drugs Eight weeks of treatment with Epclusa cured almost all people with HCV receiving opioid substitution therapy Keith Alcorn / 12 April 2018 An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area, ... Pan-genotypic regimens New affordable hepatitis C combination shows 97% cure rate Keith Alcorn / 12 April 2018 The combination of sofosbuvir and the new NS5A inhibitor ravidasvir cured 97% of people with hepatitis C in a study carried out in Malaysia, and could provide a safe and ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive